Perceptive Advisors Llc Buys Nautilus Biotechnology Inc, Singular Genomics Systems Inc, Nautilus Biotechnology Inc, Sells Atea Pharmaceuticals Inc, Atea Pharmaceuticals Inc, Allogene Therapeutics Inc

• New Purchases: NAUT, OMIC, NAUT, OMIC, ZY, ZY, MDT, MDT, CMAX, APLS, RAIN, CMAX, TMCI, AXSM, APLS, RAIN, TMCI, AXSM, BCAB, XLRN, GRPH, BCAB, RGEN, XLRN, CLDX, INBX, GRPH, RGEN, INBX, CLDX, DAWN, DAWN, VRDN, CMLTU, VRDN, CVRX, CMLTU, CVRX, SMIHU, DNAY, SMIHU, DNAY, PRVA, AKYA, PRVA, AKYA, PRTA, PRTA, FULC, FULC, TKNO, TKNO,
• Added Positions: UTHR, UTHR, IOVA, IOVA, XENE, XENE, ALDX, ALDX, CATB, CRNX, CRNX, HRMY, HRMY, ACRS, HCAT, FOLD, ACRS, HCAT, FOLD, CMLF, CMLF, RGNX, RGNX,
• Reduced Positions: AVIR, AVIR, MRTX, MRTX, GBT, GBT, TVTX, TVTX, CCCC, CCCC, NARI, NARI, NVTA, NVTA, PRVB, PRVB, FREQ, FREQ, ESTA, ESTA, EXAS, EXAS, MREO, MREO, NBIX, NBIX, KOD, KOD, SILK, SILK, VYNE, VYNE, ONCR, ONCR, KRON, KRON, ARWR, TCRR, TCRR, ARWR, HZNP, HZNP, RCKT, RCKT, ACCD, ACCD, CTMX, CTMX, FDMT, FDMT, TSHA, TSHA, CATB, FUSN, FUSN, AMWL, PLXP, PLXP, AMWL, RNA, RNA,
• Sold Out: ALLO, ARNA, ACAD, FMTX, CMPS, PCVX, SNDX, VINC, PHR, TXMD, VRAY, TLIS, CVM, DFHT, SANA,

For the details of PERCEPTIVE ADVISORS LLC's stock buys and sells, go to https://www.gurufocus.com/guru/perceptive+advisors+llc/current-portfolio/portfolio

1. Mirati Therapeutics Inc (MRTX) - 3,185,898 shares, 7.46% of the total portfolio. Shares reduced by 8.31%
2. BridgeBio Pharma Inc (BBIO) - 7,756,928 shares, 6.85% of the total portfolio.
3. Mirati Therapeutics Inc (MRTX) - 3,185,898 shares, 6.68% of the total portfolio. Shares reduced by 8.31%
4. BridgeBio Pharma Inc (BBIO) - 7,756,928 shares, 6.14% of the total portfolio.
5. SpringWorks Therapeutics Inc (SWTX) - 4,849,912 shares, 5.79% of the total portfolio.

Perceptive Advisors Llc initiated holding in Nautilus Biotechnology Inc. The purchase prices were between $9.04 and $11, with an estimated average price of $9.86. The stock is now traded at around $7.845000. The impact to a portfolio due to this purchase was 1.3%. The holding were 8,911,151 shares as of 2021-06-30.

Perceptive Advisors Llc initiated holding in Singular Genomics Systems Inc. The purchase prices were between $23.16 and $31.17, with an estimated average price of $25.88. The stock is now traded at around $16.780000. The impact to a portfolio due to this purchase was 1.23%. The holding were 3,082,870 shares as of 2021-06-30.

Perceptive Advisors Llc initiated holding in Nautilus Biotechnology Inc. The purchase prices were between $9.04 and $11, with an estimated average price of $9.86. The stock is now traded at around $7.845000. The impact to a portfolio due to this purchase was 1.17%. The holding were 8,911,151 shares as of 2021-06-30.

Perceptive Advisors Llc initiated holding in Singular Genomics Systems Inc. The purchase prices were between $23.16 and $31.17, with an estimated average price of $25.88. The stock is now traded at around $16.780000. The impact to a portfolio due to this purchase was 1.1%. The holding were 3,082,870 shares as of 2021-06-30.

Perceptive Advisors Llc initiated holding in Zymergen Inc. The purchase prices were between $28.5 and $48.5, with an estimated average price of $39.32. The stock is now traded at around $11.482500. The impact to a portfolio due to this purchase was 0.95%. The holding were 1,633,332 shares as of 2021-06-30.

Perceptive Advisors Llc initiated holding in Zymergen Inc. The purchase prices were between $28.5 and $48.5, with an estimated average price of $39.32. The stock is now traded at around $11.482500. The impact to a portfolio due to this purchase was 0.85%. The holding were 1,633,332 shares as of 2021-06-30.

Perceptive Advisors Llc added to a holding in United Therapeutics Corp by 252.46%. The purchase prices were between $167.27 and $211.93, with an estimated average price of $190.06. The stock is now traded at around $207.335000. The impact to a portfolio due to this purchase was 1.15%. The holding were 616,802 shares as of 2021-06-30.

Perceptive Advisors Llc added to a holding in United Therapeutics Corp by 252.46%. The purchase prices were between $167.27 and $211.93, with an estimated average price of $190.06. The stock is now traded at around $207.335000. The impact to a portfolio due to this purchase was 1.03%. The holding were 616,802 shares as of 2021-06-30.

Perceptive Advisors Llc added to a holding in Iovance Biotherapeutics Inc by 26.68%. The purchase prices were between $16.33 and $33.07, with an estimated average price of $26.06. The stock is now traded at around $22.390000. The impact to a portfolio due to this purchase was 0.87%. The holding were 10,959,772 shares as of 2021-06-30.

Perceptive Advisors Llc added to a holding in Iovance Biotherapeutics Inc by 26.68%. The purchase prices were between $16.33 and $33.07, with an estimated average price of $26.06. The stock is now traded at around $22.390000. The impact to a portfolio due to this purchase was 0.78%. The holding were 10,959,772 shares as of 2021-06-30.

Perceptive Advisors Llc added to a holding in Xenon Pharmaceuticals Inc by 225.99%. The purchase prices were between $16.81 and $20, with an estimated average price of $18.43. The stock is now traded at around $16.980000. The impact to a portfolio due to this purchase was 0.31%. The holding were 1,678,973 shares as of 2021-06-30.

Perceptive Advisors Llc added to a holding in Xenon Pharmaceuticals Inc by 225.99%. The purchase prices were between $16.81 and $20, with an estimated average price of $18.43. The stock is now traded at around $16.980000. The impact to a portfolio due to this purchase was 0.28%. The holding were 1,678,973 shares as of 2021-06-30.

Perceptive Advisors Llc sold out a holding in Allogene Therapeutics Inc. The sale prices were between $23.49 and $35.8, with an estimated average price of $28.67.

Perceptive Advisors Llc sold out a holding in Arena Pharmaceuticals Inc. The sale prices were between $60.48 and $73.34, with an estimated average price of $65.24.

Perceptive Advisors Llc sold out a holding in ACADIA Pharmaceuticals Inc. The sale prices were between $19.4 and $27.42, with an estimated average price of $22.66.

Perceptive Advisors Llc sold out a holding in Forma Therapeutics Holdings Inc. The sale prices were between $22.86 and $30.95, with an estimated average price of $26.91.

Perceptive Advisors Llc sold out a holding in Compass Pathways PLC. The sale prices were between $32.29 and $39.68, with an estimated average price of $35.75.

Perceptive Advisors Llc sold out a holding in Vaxcyte Inc. The sale prices were between $16.45 and $24.06, with an estimated average price of $20.48.